Who owns TRAVERE THERAPEUTICS INC (TVTX?
- CUSIP Number: 89422gaa5
Tip: Access positions for across all investors
Analyze quarterly positions in Travere Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Travere Therapeutics stock
Who bought or sold TRAVERE THERAPEUTICS INC (TVTX this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Tenor Capital Management | 50M | $93M | 55% | Jun 2026 |
|
| Linden Advisors | 28M | $52M | -72% | Jun 2026 |
|
| Henderson Group | 4.8M | $6.0M | 100% | Mar 2026 |
|
| Lazard Asset Management | 4.1M | $77k | 100% | Jun 2026 |
|
| Goldman Sachs Group | 1.8M | $3.3M | -62% | Jun 2026 |
|
| FMR | 1.5M | $2.7M | -87% | Jun 2026 |
|
| Kohlberg Kravis Roberts & Co | 382k | $709k | -56% | Jun 2026 |
|
| Royal Bank of Canada | 326k | $603k | 359% | Jun 2026 |
|
| Advent Capital Management | 216k | $403k | -99% | Jun 2026 |
|
| Citigroup | 50k | $63k | 100% | Mar 2026 |
|
| Branch Banking & Trust Company | 41k | $65k | 0% | Jun 2026 |
|
Who sold out of Travere Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Context Capital Management | Mar 2026 | 53M | $67M |
| D. E. Shaw & Co | Mar 2026 | 38M | $48M |
| Graham Capital Management | Mar 2026 | 17M | $21M |
| Shenkman Capital Management | Mar 2026 | 9.7M | $12B |
| Lord, Abbett & Co | Mar 2026 | 9.1M | $12M |
| M&G | Mar 2026 | 5.1M | $6.5M |
| BlackRock | Mar 2026 | 5.0M | $6.3M |
| Two Sigma Investments | Mar 2026 | 3.0M | $3.8M |
| Agf Management | Mar 2026 | 1.6M | $2.0M |
| Morgan Stanley | Dec 2025 | 1.3M | $1.9M |
| UBS Group | Mar 2026 | 1.2M | $1.5M |
| Union Bancaire Privee, UBP SA | Mar 2026 | 325k | $342k |
| Jane Street | Mar 2026 | 300k | $380k |
| Barclays | Mar 2026 | 250k | $314k |
| Leucadia National Corporation | Mar 2026 | 45k | $57k |